

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **GRANT OF OPTIONS PURSUANT TO 2025 SHARE INCENTIVE SCHEME**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on April 13, 2026, the Company has resolved to grant share options (the “**Options**”) to one eligible participant (the “**Grantee**”), to subscribe for an aggregate of 400,000 H shares of the Company (the “**H Shares**”) pursuant to the 2025 Share Incentive Scheme (the “**Share Scheme**”) adopted by the Company on October 24, 2025. Unless otherwise defined, capitalized terms shall have the same meaning as defined in the Share Scheme.

Details of the Options are as follows:

Date of grant                      April 13, 2026 (the “**Date of Grant**”)

Number of Grantee                One Grantee (the Grantee is an employee of the Group)

Exercise price of the Options granted	<p>HK\$23.472 per Share, being the higher of:</p> <p>(i) the closing price of HK\$23.020 per Share as stated in the daily quotations sheet issued by The Stock Exchange of Hong Kong Limited (the “<b>Stock Exchange</b>”) on the Date of Grant; and</p> <p>(ii) the average closing price of HK\$23.472 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant</p>
Number of Options granted	An aggregate of 400,000 Options, all of which were granted to one employee of the Group (each Option shall entitle the holder of the Option to subscribe for one Share)
Validity period of the Options	From the Date of Grant until October 23, 2035.
Exercise period	The Options vested in accordance with the vesting schedule as set out in the grant letter in relation to this Grant (the “ <b>Grant Letter</b> ”) may be exercised by the Grantee at any time until October 23, 2035.
Vesting period of the Options	<p>All of the Options shall vest in a single tranche on or before 31 December 2028, provided that the vesting period shall in any event be no less than 12 months.</p> <p>The vesting date of the Option will be determined by the Administrative Committee with reference to the performance targets as set out in the Grant Letter.</p>
Performance targets	The vesting of the Options granted to the Grantee will be subject to the financial performance of the subsidiary of the Company where the Grantee belongs to, and individual’s comprehensive performance evaluation, which shall be based on performance targets and evaluation rules set by the Administrative Committee set in the Grant Letter in line with business development goals.
Lock-up period	The Options and underlying shares will be locked up until earlier of (i) three months after the Company holding 100% equity interest of Optimed Medizinische Instrumente GmbH, a subsidiary of the Company; and (ii) December 31, 2028.

Clawback mechanism      In the event that any circumstances as specified in the rules of the Share Scheme and/or the respective grant letter arise, which include among others, the termination of the relevant Grantee's employment or service by the Company or any of its subsidiaries for cause, the Options granted but unvested will automatically lapse in respect of the underlying Shares with effect upon the occurrence of the relevant circumstances, unless otherwise determined by the Administrative Committee.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries: (i) no financial assistance has been provided by the Group to the Grantee for the purchase of shares under the Share Scheme; (ii) the Grantee is not a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (iii) the Grantee is not a related entity participant or service provider (as defined under the Listing Rules); and (iv) the Grantee is not a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules.

Subsequent to the grant of Options, the number of Shares available for future grants pursuant to the Share Scheme is 17,416,648 Shares and, among which, the number of Shares available for future grant under the service provider limit of the Share Scheme is 3,237,858 Shares.

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, April 14, 2026

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.*